

HR 2455

Ensuring Timely Access to Generics Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: May 1, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (May 2, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/2455>

Sponsor

Name: Rep. Joyce, John [R-PA-13]

Party: Republican • **State:** PA • **Chamber:** House

Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Brindisi, Anthony [D-NY-22]	D · NY		May 1, 2019
Rep. Crow, Jason [D-CO-6]	D · CO		May 28, 2019
Rep. Waltz, Michael [R-FL-6]	R · FL		May 28, 2019
Rep. Wright, Ron [R-TX-6]	R · TX		May 28, 2019
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Jun 5, 2019
Rep. Smucker, Lloyd [R-PA-11]	R · PA		Jun 13, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 2, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 3384	Related bill	Mar 3, 2020: Read twice and referred to the Committee on Finance.
116 S 1169	Identical bill	Apr 11, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Ensuring Timely Access to Generics Act of 2019

This bill requires the Food and Drug Administration (FDA) to consider certain factors in determining whether a petition is submitted for the primary purpose of delaying the approval of a drug application.

The FDA must (1) publish a list of petitions that were submitted with an intent to delay, and (2) establish procedures to refer such petitions to the Federal Trade Commission.

The FDA may establish a timeline for submitting petitions.

Actions Timeline

- **May 2, 2019:** Referred to the Subcommittee on Health.
- **May 1, 2019:** Introduced in House
- **May 1, 2019:** Referred to the House Committee on Energy and Commerce.